explore -WSS

explore

author：hotspot 2025-09-14 10:06:11 - browse：51

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Drug repurposing or repositioning? The language matters
Next article： Heart disease in astronauts blamed on cosmic radiation

WSS

Study links childhood stress with decline in older age

HIV drugs protect against transmission, even in unprotected sex

Personalized medicine goes far beyond genetics

Woman returns to dialysis after doctors remove transplanted pig kidney

Woman returns to dialysis after doctors remove transplanted pig kidney

Intellia reports positive results for its CRISPR

knowledge

explore

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

HIV drugs protect against transmission, even in unprotected sex

The high cost of giving birth even with insurance

The a glaring gap in research on serious mental illness and primary care

State Dept. review finds Biden bears some blame for Afghanistan failures

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Apple is now the first public company to be valued at $3 trillion

With trial win, GSK could get blood cancer drug back on market

Medicare proposal to cover medical devices draws a mixed reaction

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

focus

It costs an awful lot of money to give away a kidney

When waiting feels immoral: Empathy in the emergency department

BMI, flaws aside, is found to be useful estimate of body fat in youth

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

The Pandemic Treaty must support building strong health systems

With trial win, GSK could get blood cancer drug back on market

focus

focus

entertainment

entertainment